Literature DB >> 22977518

Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma.

Kohta Imashimizu1, Kazu Shiomi, Masahiro Maeda, Naoko Aoki, Kiyoko Igarashi, Fumio Suzuki, Mitsuru Koizumi, Kenji Suzuki, Okio Hino.   

Abstract

A large-scale screening involving the measurement of N-ERC/mesothelin levels in blood using an ELISA system for the early diagnosis of malignant mesothelioma (MM) was carried out in individuals with a history of employment at construction sites. Approximately 30,000 subjects were screened. Of the 80 subjects with high-risk values, one male patient was diagnosed as having MM based on a PET study and histopathology. This is the first report of the pre-clinical diagnosis of MM based on blood test screening. In addition, plasma levels of N-ERC/mesothelin may be effectively used for monitoring relapse after surgery.

Entities:  

Year:  2011        PMID: 22977518      PMCID: PMC3440716          DOI: 10.3892/etm.2011.225

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  7 in total

1.  Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Authors:  Kazu Shiomi; Hideaki Miyamoto; Tatsuya Segawa; Yoshiaki Hagiwara; Akinobu Ota; Masahiro Maeda; Kazuhisa Takahashi; Kimihiko Masuda; Yukinori Sakao; Okio Hino
Journal:  Cancer Sci       Date:  2006-06-07       Impact factor: 6.716

2.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 3.  Mesothelin targeted cancer immunotherapy.

Authors:  Raffit Hassan; Mitchell Ho
Journal:  Eur J Cancer       Date:  2007-10-22       Impact factor: 9.162

4.  Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model.

Authors:  Chisato Yoshida; Chizuru Sogawa; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Tomoya Uehara; Okio Hino; Yukie Yoshii; Yasuhisa Fujibayashi; Toshimitsu Fukumura; Mitsuru Koizumi; Yasushi Arano; Tsuneo Saga
Journal:  Nucl Med Commun       Date:  2010-05       Impact factor: 1.690

5.  Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Authors:  Kazu Shiomi; Yoshiaki Hagiwara; Kouji Sonoue; Tatsuya Segawa; Kazuya Miyashita; Masahiro Maeda; Hiroshi Izumi; Kimihiko Masuda; Masataka Hirabayashi; Takao Moroboshi; Takashi Yoshiyama; Atsuko Ishida; Yuji Natori; Akira Inoue; Masashi Kobayashi; Yukinori Sakao; Hideaki Miyamoto; Kazuhisa Takahashi; Okio Hino
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

6.  Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Authors:  Raffit Hassan; Wolfgang Ebel; Eric L Routhier; Rina Patel; J Bradford Kline; Jingli Zhang; Qimin Chao; Sara Jacob; Howard Turchin; Lester Gibbs; Martin D Phillips; Shiyama Mudali; Christine Iacobuzio-Donahue; Elizabeth M Jaffee; Maria Moreno; Ira Pastan; Philip M Sass; Nicholas C Nicolaides; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-12-19

7.  Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.

Authors:  Koichi Inami; Masaaki Abe; Kazuyoshi Takeda; Yoshiaki Hagiwara; Masahiro Maeda; Tatsuya Segawa; Masafumi Suyama; Sumio Watanabe; Okio Hino
Journal:  Cancer Sci       Date:  2009-12-09       Impact factor: 6.716

  7 in total
  3 in total

1.  The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.

Authors:  Harumi Saeki; Akane Hashizume; Hiroshi Izumi; Fujihiko Suzuki; Kazuhisa Ishi; Michio Nojima; Masahiro Maeda; Okio Hino
Journal:  Oncol Lett       Date:  2012-07-11       Impact factor: 2.967

2.  Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.

Authors:  Tomoko Hirohashi; Kiyoko Igarashi; Masaaki Abe; Masahiro Maeda; Okio Hino
Journal:  Mol Clin Oncol       Date:  2013-10-02

3.  Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Authors:  Tadashi Sato; Yohei Suzuki; Takanori Mori; Masahiro Maeda; Masaaki Abe; Okio Hino; Kazuhisa Takahashi
Journal:  Cancer Med       Date:  2014-07-10       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.